- Home
- IFRX vs PMVP Comparison
IFRX vs PMVP Comparison
Compare IFRX & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- PMVP
- Stock Information
- Founded
- IFRX 2007
- PMVP 2013
- Country
- IFRX Germany
- PMVP United States
- Employees
- IFRX N/A
- PMVP N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- IFRX Health Care
- PMVP Health Care
- Exchange
- IFRX Nasdaq
- PMVP Nasdaq
- Market Cap
- IFRX 65.8M
- PMVP 71.9M
- IPO Year
- IFRX 2017
- PMVP 2020
- Fundamental
- Price
- IFRX $1.30
- PMVP $1.04
- Analyst Decision
- IFRX Strong Buy
- PMVP Strong Buy
- Analyst Count
- IFRX 2
- PMVP 2
- Target Price
- IFRX $9.00
- PMVP $5.50
- AVG Volume (30 Days)
- IFRX 322.6K
- PMVP 134.4K
- Earning Date
- IFRX 05-07-2025
- PMVP 05-08-2025
- Dividend Yield
- IFRX N/A
- PMVP N/A
- EPS Growth
- IFRX N/A
- PMVP N/A
- EPS
- IFRX N/A
- PMVP N/A
- Revenue
- IFRX $171,642.00
- PMVP N/A
- Revenue This Year
- IFRX $106.72
- PMVP N/A
- Revenue Next Year
- IFRX $66.89
- PMVP N/A
- P/E Ratio
- IFRX N/A
- PMVP N/A
- Revenue Growth
- IFRX 162.79
- PMVP N/A
- 52 Week Low
- IFRX $0.82
- PMVP $0.82
- 52 Week High
- IFRX $2.82
- PMVP $2.26
- Technical
- Relative Strength Index (RSI)
- IFRX 58.32
- PMVP 46.01
- Support Level
- IFRX $0.82
- PMVP $0.95
- Resistance Level
- IFRX $1.12
- PMVP $1.14
- Average True Range (ATR)
- IFRX 0.13
- PMVP 0.10
- MACD
- IFRX 0.06
- PMVP 0.02
- Stochastic Oscillator
- IFRX 90.49
- PMVP 68.65
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.